Ibutamoren
Ibutamoren · IbutaMoren (MK-677) · MK-677 · Mk677 Sarms · L 163191 · MK-0677 · Ibutamoren, 10 mM in DMSO · IBUTAMOREN (MK-677), CID178024
Identifikatoren & physikalische Daten
| CAS No. | 159634-47-6 |
|---|---|
| Summenformel | C27H36N4O5S |
| Durchschnittliche Molmasse | 528,7 g/mol |
| Monoisotopische Masse | 528,24064144 g/mol |
| SMILES | CC(C)(N)C(=O)N[C@H](COCc1ccccc1)C(=O)N1CCC2(CC1)CN(S(C)(=O)=O)c1ccccc12 |
| InChIKey | UMUPQWIGCOZEOY-JOCHJYFZSA-N |
| PubChem CID | 178024 |
| ChEMBL | CHEMBL13817 |
| EC No. | 808-810-3 |
| DTXSID | DTXSID90166700 |
Chemische & physikalische Eigenschaften
| XLogP | 1,3 |
|---|---|
| Polarare Oberfläche (TPSA) | 130 |
| H-Brücken-Donoren | 2 |
| H-Brücken-Akzeptoren | 7 |
| Frei drehbare Bindungen | 8 |
| Schwere Atome | 37 |
| Formalladung | 0 |
| Komplexität | 920 |
| LogP (Verteilungskoeffizient) | 2.37 |
| Dichte | 1.32 |
| pKa (Säurekonstante) | 15.73±0.46(Predicted) |
| Aggregatzustand | Solid |
| Farbe | White to off-white |
| InChIKey | UMUPQWIGCOZEOY-JOCHJYFZSA-N |
| SMILES | C(N[C@H](COCC1=CC=CC=C1)C(N1CCC2(CC1)C1=C(N(S(C)(=O)=O)C2)C=CC=C1)=O)(=O)C(N)(C)C |
Sicherheit & Vorschriften
| GHS-Einstufung | DangerH301 (100%): Toxic if swallowed [Danger Acute toxicity, oral]P264, P270, P301+P316, P321, P330, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 38 reports by companies from 1 notifications to the ECHA C&L Inventory. |
|---|---|
| Hazard Classes and Categories | Acute Tox. 3 (100%) |
| Alarmwort | Achtung |
| Gefahrenhinweise | Code Gefahrenhinweise Gefahrenklasse Abteilung Alarmwort Symbol P-Code H301 |
Anwendungen & Verwendung
Beschreibung
Ibutamoren (INN) (developmental code names MK-677, MK-0677, L-163,191)is a non-peptidic, potent, long acting, orally-active, and selective agonist of the ghrelin receptor and a growth hormone secretagogue, mimicking the growth hormone (GH)-stimulating action of the endogenous hormone ghrelin. It has been demonstrated to increase the release of, and produces sustained increases in plasma levels of several hormones including GH and insulin-like growth factor 1 (IGF-1), but without affecting cortisol levels. MK677 has shown to sustain activation of GH-IGF-1 Axis and increase in lean body mass but no change in total fat mass or visceral fat. It is currently under development as a potential treatment for reduced levels of these hormones, such as in children or elderly adults with growth hormone deficiency, and human studies have shown it to increase both muscle mass and bone mineral density, making it a promising therapy for the treatment of frailty in the elderly.
Verwenden
Growth hormone releasing factor.